GlassScriptPhysician profile
Laleh Bigdeli
NPI 1306139480
$9,314.03
in general payments reported to CMS, 2019-2025
48 companies · $2,096 in 2025
The $2,096 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,812 · 2020: $442 · 2021: $186 · 2022: $1,286 · 2023: $1,751 · 2024: $1,742 · 2025: $2,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,588.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,083.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,049.68 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $978.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $587.56 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Pfizer INC. | $561.18 | 2019-2025 | |
| Amgen INC. | $538.11 | 2019-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $460.78 | 2022-2025 | Rexulti |
| Abbvie INC. | $415.08 | 2019-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $336.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $312.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $303.76 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.23 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $260.85 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Astellas Pharma US INC | $235.61 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $181.45 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laleh Bigdeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.